Canada markets closed

Alpha Tau Medical Ltd. (DRTS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.4900+0.1200 (+5.06%)
At close: 04:00PM EDT
2.5800 +0.09 (+3.61%)
After hours: 05:16PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.3700
Open2.4300
Bid2.4000 x 100
Ask2.5300 x 100
Day's Range2.3900 - 2.4900
52 Week Range2.1500 - 4.8000
Volume45,860
Avg. Volume34,619
Market Cap173.48M
Beta (5Y Monthly)0.71
PE Ratio (TTM)N/A
EPS (TTM)-0.4200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.25
  • GlobeNewswire

    Alpha Tau to Participate in May Investor Conferences

    JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present at the following investor conferences in May 2024. Event:Guggenheim Securities Radiopharmaceuticals DayFormat:PresentationDate:May 13, 2024Time:11:30AM ETLocation:New York, NY Event:H.C. Wainwright 2ndAnnual BioConnect Investor ConferenceFormat:Fireside

  • GlobeNewswire

    Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

    JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Radiopharma Innovation Summit on April 11th, 2024. Event:Jefferies Radiopharma Innovation SummitDate:April 11, 2024Time:12:40-1:10 PM ESTLocation:New York, NY Mr. Levy will also be available for 1x1 inv

  • GlobeNewswire

    Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

    - Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs of potential dose response findings - - ReSTART U.S. multi-center pivotal trial currently underway - - Submitted PMDA application for recurrent Head and Neck cancer in Japan - - Entered into long-term lease for a second facility in the U.S. in Hudson, NH - - Cash, deposits and restricted deposits balance of $84.9 million, with anticipated runway for at least two years - JERUSALEM, March 07